BANGALORE: After three major U.S. companies -Boeing, Abbott and Honeywell - auto major Maruti Suzuki has now come in support of India's intellectual property rights (IPR) regime, saying the "very strong" domestic laws are on par with international standards. American pharma sector had alleged that Indian IPR laws discriminate against U.S. companies and violate global norms. "
MSI said: "Many recent judgments have proved that strong patent law not only secures the rights of patentee, but also ensures genuine public need. The IPR law in India provides transparent system of securing and enforcing the patent rights." It also said that the Indian government grants patents to encourage inventions. "We have not observed any violation of our IP rights and our rights are fully secured under Indian IP laws," it added.
The company, however, said that "further betterment in the processes would always help stakeholders and the awareness to enforcement agencies for proper execution of laws". MSI has one of the biggest automobile R&D set-ups in India, where it develops technologies and files IPR for them. Earlier, U.S. defence major Honeywell, civil aviation firm Boeing and drug firm Abbott had come out strongly in support of India's IPR regulations.These statements assume significance against the backdrop of U.S. industry, particularly the pharmaceuticals sector, and trade lobbies putting pressure on their government to place India under the Priority Foreign Country list for IPR. Under the U.S. Trade Act, a Priority Foreign Country is the worst classification given to those that deny adequate and effective protection of IPR or fair and equitable market access to US entities, relying on IPR protection.
The U.S. Trade Representative (USTR) in its Special 301 report had kept India out of the Priority list and had said that it would hold discussions with the next government in New Delhi on enforcement and protection of IP However, the U.S. has said that they would do an 'out-of-cycle' review of India's IPR regime. The U.S. industry had raised the matter of India's rejection of patents for Bristol-Myers Squibb's Sprycel and Novartis AG's Glivec. India has always maintained that its IPR regime is fully compliant with WTO norms and it would drag the US to the global trade body if any adverse unilateral step is taken against the country in IPR-related matters.
Maruti Suzuki stock price On June 03, 2014, Maruti Suzuki India closed at 2342.85, up 16.00, or 0.69 percent. The 52-week high of the share was 2505.30 and the 52-week low was 1217.00. The company's trailing 12-month (TTM) EPS was at 92.13 per share as per the quarter ended March 2014. The stock's price-to-earnings (P/E) ratio was 25.43. The latest book value of the company is 707.16 per share. At current value, the price-to-book value of the company is 3.31.